- Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, was approved on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term.
- The full address and contact details of the Shanghai branch are found at the end of this announcement.
Lugano, Switzerland, October 17, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement.
The establishment of the new office in Shanghai reflects our long-term commitment to China and provides Helsinn with a platform to pursue commercial activities. Helsinn plans to provide innovative and high-quality products to improve the lives of people with cancer, in line with its core values of quality, integrity and respect.
With the establishment of Helsinn Pharmaceuticals (Beijing) Co. Ltd. and after the anticipated approval of the first products next year, Helsinn will continue to expand its presence in China, via a commercial arm focused on Shanghai, as well as seeking to establish pan-China collaborations with partners to prepare for the launch of future products.
Over many years, Helsinn has forged a strong presence in China, via its clinical and regulatory activities, licensing and commercial collaborations, on several of Helsinn’s supportive care products. Currently, several of these products are under registration with The China Food and Drug Administration (CFDA) with an estimated time for approval within 2018. With this continued momentum, Helsinn aims to steadily grow and become a leading player in cancer care also in China.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Helsinn has been developing a presence in China over the past five years and we have developed valuable experience, learnings and network. With the opening of our Shanghai office we will now be more visible and have the opportunity to capitalize on the groundwork we have already put in.
“China is a large, diverse and dynamic market and we’re delighted to have a permanent presence here as we expand our global footprint and seek to build out new avenues to help more people with cancer around the world.”
The address of the new office in Shanghai is:
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Shanghai Branch
5/F, 149 Yuanmingyuan Road
Phone number: +86 21 3120 3180
Official Chinese address is:
电话号码： +86 21 3120 3180
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information:
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21